Articles tagged with Colorectal Cancer
A new study reveals that high levels of dietary iron from red meat reactivates telomerase, driving colorectal cancer progression. A promising small molecule, SP2509, blocks this reaction, offering hope for targeted therapies in Singapore and globally.
A Kaiser Permanente study found that close to 39% of adults aged 45-49 returned their FIT kit, compared to nearly 38% of adults aged 50. The study suggests that adults in this age group have a similar colorectal cancer risk as those aged 50.
A systematic review of randomized clinical trials found that AI-assisted colonoscopies increased overall detection of colonic polyps and adenomas, with a small increase in procedure time. Researchers also found no clear differences in benefit for detecting adenomas across different AI systems.
Younger adults diagnosed with colorectal cancer have later-stage disease with more aggressive types of tumors. Obesity, family history, inflammatory bowel disease, and symptoms are strongly associated factors. These findings highlight disparities in colon cancer incidence among younger adults, particularly non-Hispanic Black patients.
Researchers discovered a previously unknown class of compounds in the fungus Bipolaris victoriae S27 that effectively kill colorectal cancer cells. The most effective compound, bipoterpride No. 2, targets the DCTPP1 enzyme and shows promise as a potential new treatment option.
A new study reveals how chronic stress disrupts the balance of gut microbiota to speed up the progression of colorectal cancer. The research identified a particular bacterial species as a potential therapeutic target, specifically Lactobacillus genus, which is essential for a healthy immune response against cancer.
Researchers developed a machine learning model to predict mesenteric lymph node metastasis preoperatively in colorectal cancer patients. The XGB-based model achieved high accuracy, identifying key predictors such as perineural invasion and hematocrit levels.
A new study aims to increase follow-up care for patients who receive abnormal stool-based fecal immunochemical tests, focusing on improving coordination between primary and specialty clinics. The goal is to improve colorectal cancer screening processes in underserved populations, increasing survival and reducing mortality.
A large proportion of gene variants previously classified as 'variants of uncertain significance' (VUS) have been reclassified as benign, according to a study published in the American Journal of Human Genetics. This reduces the total number of VUS by 37%, providing relief for carriers worldwide.
Researchers found that humorous comic strip cartoons increased likelihood of agreeing to take a quiz on personal risk for colon cancer. Exposing people to funny content reduced information avoidance, making them more likely to choose to watch a video about colorectal cancer prevention.
A double-blind randomized phase 3 clinical trial found no additional benefits from high-dose vitamin D3 when added to standard chemotherapy for patients with untreated metastatic colorectal cancer. However, a potential benefit was observed for left-sided disease patients.
A single-center cohort study identified substantial overall survival disparity among racial and ethnic groups, with socioeconomic status contributing less than a third of the disparity. Tumor molecular features also played a significant role in the disparities found in colorectal cancer survival.
A new study published in Annals of Oncology found that long-course radiotherapy is safer and more effective than short-course radiotherapy for preserving organs in rectal cancer patients. The treatment was shown to prevent regrowth of the primary tumour, but had similar overall survival rates.
Researchers at NTU Singapore and Oxford have identified a new process called nucleophagy that helps cells remove harmful DNA-protein lesions, promoting genetic material stability and cell survival. This discovery may improve cancer treatment outcomes for patients with colorectal cancer.
Researchers found that omitting the bolus-specific 5-fluorouracil (5-FU) portion from common chemotherapy regimens improves tolerability without sacrificing treatment effectiveness. The study of 11,765 patients shows no decrease in overall survival but a notable reduction in cytopenias.
Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.
Patients with early-onset colorectal cancer living in rural areas had lower 5-year survival rates compared to urban counterparts. Persistent poverty in these areas may compound this association, affecting overall survival outcomes.
Researchers found that CHEK2 variants do not increase colorectal cancer risk compared to controls. Three low-risk missense variants were identified as potential drivers of breast cancer risk variability.
A University of Oklahoma researcher has been awarded a NIH grant to evaluate thousands of natural products with therapeutic potential. The goal is to identify specific components of these products that have anticancer properties and understand how they work.
A new treatment approach has been confirmed effective in a major study, showing that locally advanced rectal cancer patients can experience complete tumour disappearance without needing surgery. This method reduces the risk of recurrence and preserves normal bowel function, offering a promising alternative to traditional treatments.
Researchers discuss the role of gut microbiota in regulating basal inflammation levels and promoting healing of the bowel after surgery. Weakened gut barrier function may lead to persistent low-grade inflammation and increased risk of cancer recurrence.
The study analyzes six major digestive system cancers worldwide and in China, revealing correlations between country HDI and cancer prevalence. Colorectal cancer is the most prevalent, while Asia accounts for 60.5% of new gastrointestinal cancer cases globally.
A new Cleveland Clinic study reveals that diet-derived molecules called metabolites are the main drivers of young-onset colorectal cancer risk, particularly those associated with red and processed meat. The research suggests that addressing diet with doctors can help prevent colon cancer in younger adults.
The study identified 96 mutated driver genes, 9 of which were previously unknown in CRC, and 24 that were new to any form of cancer. A new molecular classifier system was developed, identifying five distinct CRC prognostic subtypes with unique molecular characteristics.
A clinical trial in Denmark found that offering women further screening opportunities during breast cancer screenings significantly increased their participation and enabled early diagnosis of other cancers. The study used a cluster-randomized crossover design and involved over 27,000 participants.
Researchers discuss diverse BRAF alterations found in human cancers and strategies to inhibit them. Class I BRAF inhibitors represent a landmark achievement in precision oncology, with FDA-approved dabrafenib/trametinib for metastatic BRAF p.V600E-mutant solid tumors.
A study published in JAMA Oncology found that regular aspirin use significantly lowers the risk of colorectal cancer in individuals with higher lifestyle-related risk factors. The benefits were most pronounced among those with unhealthiest lifestyles, where treating 78 patients with aspirin would prevent one case of colorectal cancer o...
A cohort study found that aspirin use was associated with a greater absolute reduction in risk of colorectal cancer among individuals with less healthy lifestyles. Lifestyle risk factors may help identify those with a more favorable risk-benefit profile for cancer prevention with aspirin.
Researchers identified areas with lower colorectal cancer screening rates and developed an interactive web map to pinpoint neighborhood-level disparities. The study aims to inform targeted education or intervention programs, ultimately increasing screening rates in priority neighborhoods and contributing to national improvements.
A new AI algorithm assesses immune cells in early-stage bowel cancer tumours to predict recurrence risk. The CD3 Score test has been shown to reliably identify high-risk cancers that are more likely to recur within five years of surgery, enabling clinicians to make informed decisions about chemotherapy treatment.
A study published in JAMA Surgery shows that liver transplants significantly improve progression-free survival rates for patients with unresectable colorectal liver metastases compared to other therapies. At three years, 90% of transplant patients remained cancer-progression free, whereas only 42% of those receiving alternative treatme...
A new study published in JAMA Network Open shows that an at-home fecal immunochemical testing (FIT) screen can reduce the risk of colorectal cancer death by 33%, comparable to screening colonoscopy. FIT is a non-invasive test that involves mailing a stool sample to the laboratory for analysis.
Researchers found that eliminating racial disparities in follow-up colonoscopy rates and quality would significantly reduce colorectal cancer incidence and mortality. By closing these gaps, the study aims to achieve health equity and find innovative solutions for true change.
Cancer cells can attach themselves to liver cells when specific proteins are present, allowing them to colonize and form new tumors. This discovery provides insights into the metastatic process and may lead to potential treatments that prevent cancer from establishing new tumors.
Colorectal cancer treatment is limited by existing therapies, but epigenetic modifiers offer a novel approach. DNMT and TET inhibitors have been identified as promising therapeutic strategies to restore normal gene function and combat CRC.
A nested case-control study found that completing fecal immunochemical tests lowers overall death risk from colorectal cancer, particularly in the left colon. The association was observed across racial and ethnic groups, supporting its use in population-based screening strategies.
Researchers have identified a potential biomarker, CXCL13, that correlates with treatment response and prognosis in patients with metastatic colorectal cancer. High levels of CXCL13 are associated with positive treatment response and improved survival, while low levels indicate non-response and poorer prognosis.
The study confirms the effectiveness of 12 standards in reducing hospital length of stay, costs, and complication rates. Standardized care protocols across multiple phases of surgical care lead to improved patient outcomes and hospital efficiency.
Researchers found that regorafenib synergizes with TAS102 to inhibit cancer growth, angiogenesis, and microvessel density in preclinical models of colorectal and gastric cancers. The combination also suppresses ERK1/2 activation regardless of KRAS or BRAF mutational status.
Cutting processed meat intake by 30% reduces the risk of diabetes, cardiovascular disease, and colorectal cancer. The study found that this reduction would lead to over 350,000 fewer diabetes cases and tens of thousands fewer cardiovascular disease and colorectal cancer cases.
African American woman breast cancer survivor talking about her experience with breast cancer and the impact of breast cancer on women's lives. The American Cancer Society is a leading organization in cancer research, patient services, and advocacy.
Immunotherapy has emerged as a promising approach in treating metastatic colorectal cancer, especially for patients with dMMR/MSI-H tumors. The use of immune checkpoint inhibitors has shown favorable outcomes in clinical trials, including improved progression-free survival and disease control rates.
Researchers have identified a new potential target for colorectal cancer treatment in the form of the protein PFDN6. Studies found that PFDN6 levels are increased in CRC patients, contributing to tumor growth and cell migration. Reducing PFDN6 in lab studies slowed cancer cell spread and increased cell death.
AlphaFold's groundbreaking ability to predict protein structures is set to transform predictive medicine, enabling the development of personalized vaccines and adaptive clinical trials. However, the review also highlights crucial challenges and ethical considerations surrounding AI integration with clinical data.
Researchers at NTNU have developed a way to reconstruct 3D models of the colon using single images taken by capsule endoscopy cameras. These models can aid in detecting abnormalities and signs of disease, enabling specialists to make diagnoses faster.
Researchers at Virginia Tech have discovered a possible new pathway to treat colorectal cancer by targeting the NF-kB-inducing kinase (NIK) protein. The study, led by Irving Coy Allen, identifies changes in a significant signaling pathway in human patients and presents potential targets for therapeutics.
Researchers at Weill Cornell Medicine developed an artificial intelligence-powered method for detecting tumor DNA in blood, showing high sensitivity and accuracy in predicting cancer recurrence. The technology, called MRD-EDGE, can detect subtle patterns in sequencing data to distinguish between cancer and non-cancerous signals.
A new trial indicates that immunotherapy could successfully treat the most common form of colorectal cancer. The study, published in Nature Medicine, found that botensilimab and balstilimab caused tumours to shrink or remain stable in 61% of patients with microsatellite stable metastatic colorectal cancer.
Researchers from IBEC investigated how mechanical properties of colorectal cancer stem cells influence metastasis. Cells expressing LGR5 protein exhibit softer, less sticky properties and better adhere to blood vessel walls.
Researchers developed an oral inulin-based hydrogel targeting colorectal tumors, which released oxaliplatin and modulated the microbiota to generate anti-tumor immune responses. The treatment showed improved chemotherapy efficacy and reduced tumor progression.
Researchers found that metformin increases levels of microRNAs miR-2110 and miR-132-3p, targeting genes PIK3R3 and STMN1 to slow down cancer cell growth and division. This study provides new insights into metformin's molecular mechanisms and its potential as a preventive agent for reducing cancer growth.
Researchers have developed a novel approach to treat colorectal cancer using simultaneous delivery of alpha- and beta-radionuclides, significantly reducing side effects. The therapy, known as pretargeted dual-isotope radionuclide therapy, has been shown to be effective in inducing tumor shrinkage and cures.
A recent NTU Singapore study found that eight in ten gastroenterologists accept and trust the use of AI-powered tools in diagnosing and assessing colorectal polyps. The study, which surveyed 165 doctors in the Asia-Pacific region, also found that more experienced gastroenterologists perceived a lower risk of AI tools.
This study found that lowering the fecal immunochemical test positivity threshold can achieve comparable sensitivity and specificity to the multitarget stool RNA test without additional testing. The findings are similar to previous observations with multitarget stool DNA testing, suggesting a potentially simpler screening method.
Research led by Weill Cornell Medicine found that most colorectal cancers begin with the loss of intestinal stem cells, even before cancer-causing genetic alterations appear. This new understanding suggests a unified model for colorectal cancer initiation where damage to intestinal crypts causes a decrease in aPKC protein expression.
A study by UCLA Health Jonsson Comprehensive Cancer Center researchers found that combining experimental immunotherapy drugs with chemotherapy significantly improves progression-free survival and overall survival for patients with metastatic colorectal cancer. The median progression-free survival was 6.2 months compared to 2.1 months f...
A Kaiser Permanente study of 316,443 patients reveals that 7.4% repeated fecal testing instead of proceeding to a colonoscopy, and only 41% received a colonoscopy within one year of their initial positive test. Patients who repeated home tests cited concerns about colorectal cancer diagnosis
Studies reveal distinct differences in oral microbiomes of patients with gastric cancer, premalignant conditions, and healthy controls. Researchers also found a surge in colorectal cancer incidence among young patients under 45, while late-stage gallbladder cancer is on the rise in non-Hispanic Blacks.
A study led by the University of Pennsylvania School of Medicine found that offering patients a choice between colonoscopy and at-home tests more than doubled colorectal cancer screening rates. Approximately 10% of participants received colonoscopies, while around 11% completed at-home fecal immunochemical tests.
A meta-analysis suggests combining microsatellite instability (MSI) and tumor-infiltrating lymphocytes (TIL) can optimize prognostic assessment in early-stage colorectal cancer. Patients with high MSI and TIL had the best prognosis, while those with low immune cells found in the tumor tissue had a poor outcome.